allogeneic cd34+ cells
Cell therapyexperimental
Clinical trial activity
10 trials · 12 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2002 (NCT00586274)
Timeline
Indications
Studied for
- Astrocytoma · Phase 1
- Ependymoma · Phase 1
- Extracorporeal Circulation · Phase 2
- Fanconi Anemia · Phase 1
- Glioblastoma · Phase 1
- Glioma · Phase 1
- Heart Failure · Phase 2
- Immune Tolerance · Phase 1
- Kidney Failure, Chronic · Phase 1
- Kidney Transplantation · Phase 1/Phase 2
- Leukemia, Lymphoid · Phase 1
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Phase 1
- Leukemia, Myeloid, Acute · Phase 1/Phase 2
- Lymphoma · Phase 1
- Myelodysplastic Syndromes · Phase 1
- Oligodendroglioma · Phase 1
- Primary Myelofibrosis · Phase 1
- Renal Insufficiency, Chronic · Phase 1/Phase 2
Mechanism of action
- Unspecified targetTissue restoration
tissue restoration
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- cd34 selected haploidentical pbsct
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07031765 | Phase 1 | Jul 25, 2025 | Florida Department of Health, University of Florida |
| NCT06047886 | Phase 1 | Jun 30, 2024 | University of Alabama, Birmingham |
| NCT05806749 | Phase 1 | Jul 7, 2023 | University of California, Los Angeles |
| NCT06154044 | Phase 2 | May 1, 2022 | University of Ljubljana |
| NCT04982354 | Phase 1/Phase 2 (Phase 2) | Dec 15, 2021 | Baptist Health, Jazz Pharmaceuticals |
| NCT04990427 | Phase 1/Phase 2 (Phase 2) | Sep 15, 2021 | Caladrius Biosciences |
| NCT03707262 | Phase 1/Phase 2 (Phase 2) | Feb 25, 2019 | OneLegacy Foundation, University of California, Los Angeles |
| NCT00632034 | N/A | May 31, 2010 | Imperial College London |
| NCT00586274 | Phase 1 | Mar 1, 2002 | Baylor University, The University of Texas, Dallas |
| NCT06731036 | N/A | — | University of Florida |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (12)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of California, Los Angeles | Academic/Hospital | 2 | 2 | 2 | 2019 |
| University of Florida | Academic/Hospital | 2 | 2 | 2 | 2025 |
| Baptist Health | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Baylor University | Academic/Hospital | 1 | 1 | 1 | 2002 |
| Caladrius Biosciences | For profit | 1 | 1 | 1 | 2021 |
| Florida Department of Health | Government | 1 | 0 | 1 | 2025 |
| Imperial College London | Academic/Hospital | 1 | 1 | 1 | 2010 |
| Jazz Pharmaceuticals | For profit | 1 | 0 | 1 | 2021 |
| OneLegacy Foundation | Academic/Hospital | 1 | 0 | 1 | 2019 |
| The University of Texas, Dallas | Academic/Hospital | 1 | 0 | 1 | 2002 |
| University of Alabama, Birmingham | Academic/Hospital | 1 | 1 | 1 | 2024 |
| University of Ljubljana | Academic/Hospital | 1 | 1 | 1 | 2022 |
12 organizations
Page 1 / 1